NCT01124747

A Study to Assess the Systemic Disposition of ASP1585 After Administration of 14C-labeled Drug

An Open-Label Study to Evaluate the Disposition of 14C-Labeled ASP1585 in Healthy Male Volunteers

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: Astellas Pharma Inc · Industry
• Sex: Male
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The objective of this study is to assess the systemic disposition of ASP1585 after oral administration of 14C-labeled drug in healthy male subjects.

Detailed description

Subjects will receive study drug for 18 days with a radioactive dose of study drug given on Day 15. Blood, urine and feces will be collected to confirm recovery of radioactivity.

Conditions

• Healthy
• Pharmacokinetics of ASP1585

Interventions

Type	Name	Description
DRUG	ASP1585	Oral
DRUG	14C-Labeled ASP1585	Oral

Timeline

• Start date: 2010-04-01
• Primary completion: 2010-05-01
• Completion: 2010-05-01
• First posted: 2010-05-17
• Last updated: 2014-05-05

Locations

1 site across 1 country: United States